InflaRx NV
Closed
2.23 -5.11
Overview
Share price change
24h
Min
2.21
Max
2.26
Income | 3.2M -5.7M |
|---|---|
EPS | -0.08 |
Profit margin | 16,200.567 |
Employees | 65 |
EBITDA | 8.5M -5.5M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +292.86% upside |
Market Cap | 205M 359M |
|---|---|
Previous open | 7.34 |
Previous close | 2.23 |
InflaRx NV Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
InflaRx NV Forecast
Price Target
By TipRanks
292.86% upside
12 Months Forecast
Average 8.8 USD 292.86%
High 14 USD
Low 4 USD
Based on 6 Wall Street analysts offering 12 month price targets forInflaRx NV - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About InflaRx NV
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
